
Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups
Neratinib (Nerlynx)–based combinations demonstrated consistent central nervous system (CNS) efficacy across treatment settings in patients with HER2-positive breast cancer with untreated/active or asymptomatic/stable brain metastases, according to …